Gapping up
In reaction to strong earnings/guidance:
In reaction to strong earnings/guidance:
- ASML +6.7%, ORBK +3.4%, PNFP +1%, USB +0.9%, BAC +0.5%
M&A news:
- JUNO +59.5% (WSJ reporting CELG / JUNO in merger talks)
Select Juno peers showing strength:
- ADAP +8.4%, BLUE +7.1%, BLCM +6.4%, ZIOP +3.8%, GILD +0.5%
Other news:
- NURO +72.7% (announces collaboration with GlaxoSmithKline (GSK) involving Quell Wearable Pain Relief Technology; GSK to pay the co $5 mln and up to $21.5 mln in milestones)
- AEZS +37.7% (enters into licensing and assignment agreement with Strongbridge (SBBP) for Macrilen (macimorelin) in the U.S. and Canada)
- NEWA +14.6% (Newater Technology +25% after announcing new strategic partnership with NW Blockchain Limited to jointly develop blockchain applications to use in the wastewater treatment industry)
- ONTX +11.5% (announces that it is moving forward with its Phase 3 INSPIRE pivotal trial following the promising interim analysis)
- VRS +9.7% (expanded its evaluation of potential transaction alternatives to include other alternatives, including but not limited to, a potential sale or merger of the entire company)
- BLRX +6.5% (announces partial monotherapy results from Phase 2a COMBAT study in pancreatic cancer)
- SEII +6.2% (entered into a cooperation agreement with CoAssets Pte for the development of a blockchain-enabled financial transaction system and mobile application)
- TAT +5.7% (TransAtlantic Petroleum has formed strategic committee and engaged financial advisor to market the Company and explore strategic alternatives)
- EGO +4.4% (reports 2017 gold production of 285,919 ounces vs revised guidance of 280,000-310,000 ounces and prelim 2018 guidance; suspending cash payment of semi-annual dividend payment )
- EXEL +2.7% ( Ph 3 Trial results of cabozantinib demonstrating significant overall survival benefit in patients with previously treated advanced hepatocellular carcinoma)
Analyst comments:
- IBM +1.9% (upgraded to Overweight at Barclays)
- GRPN +1.6% (upgraded to Neutral from Sell at Goldman)
- LLL +0.8% (upgraded to Buy from Neutral at BofA/Merrill)
- BLL +0.6% (upgraded to Buy from Neutral at Citigroup)